Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL950218 | 0.85 | LMNA (0.73) | LMNASMN1; SMN2KMT2AL3MBTL1POLB | |
| SCHEMBL17842156 | 0.84 | GRM4 (0.64) | LMNASMN1; SMN2KMT2ACES2CES1 | |
| SCHEMBL3709112 | 0.80 | SMN1; SMN2 (0.67) | LMNASMN1; SMN2KMT2APOLBALDH1A1 | |
| SCHEMBL2783136 | 0.79 | KMT2A (0.51) | LMNAKMT2ACES2CES1NAPRT | |
| SCHEMBL16211860 | 0.79 | NAPRT (0.59) | LMNAKMT2ACES2CES1NAPRT | |
| SCHEMBL12143400 | 0.79 | KMT2A (0.55) | LMNAKMT2ACES2CES1NAPRT | |
| SCHEMBL31369148 | 0.78 | KMT2A (0.75) | LMNASMN1; SMN2KMT2ACES2CES1 | |
| SCHEMBL87791 | 0.78 | KMT2A (0.75) | LMNASMN1; SMN2KMT2ACES2CES1 | |
| SCHEMBL30118935 | 0.78 | KMT2A (0.58) | LMNASMN1; SMN2KMT2ACES2CES1 | |
| SCHEMBL5717594 | 0.78 | L3MBTL1 (0.64) | LMNASMN1; SMN2KMT2ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-9296740-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| EP-2010525-B1 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383630-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-7807671-B2 | Diketo-piperazine and piperidine derivatives as antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-05 | — | — | US | disclosed |
| US-7244753-B2 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| WO-2007002293-A2 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| EP-1542972-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-04-15 | — | — | US | disclosed |
| WO-2004010945-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-6136810-A | DRUGS AS ENZYME INHIBITORS OF PHOSPHODIESTERASE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| EP-0885894-A1 | PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-12-23 | — | — | EP | disclosed |
| CN-1202171-A | Pyrido [2,3-d] pyrimidine derivatives and medicinal compositions thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1998-12-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072883-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | LMNA 4147/4885SMN1; SMN2 2470/4885KMT2A 3968/4885 |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | LMNA 4347/4885SMN1; SMN2 1806/4885KMT2A 3304/4885 |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CCR1, CCR3, CCR4 | LMNA 4347/4885SMN1; SMN2 1806/4885KMT2A 3304/4885 |
| US-20110098308-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | LMNA 4347/4885SMN1; SMN2 1806/4885KMT2A 3304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.